ImmuPharma plc (LON:IMM – Get Free Report)’s share price dropped 6.3% on Tuesday . The stock traded as low as GBX 2.95 ($0.04) and last traded at GBX 2.95 ($0.04). Approximately 2,001,512 shares traded hands during mid-day trading, a decline of 90% from the average daily volume of 20,718,016 shares. The stock had previously closed at GBX 3.15 ($0.04).
ImmuPharma Trading Up 10.1 %
The company has a market cap of £12.99 million, a PE ratio of -312.00 and a beta of 1.53. The firm has a 50 day moving average of GBX 1.67 and a two-hundred day moving average of GBX 1.71.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Stories
- Five stocks we like better than ImmuPharma
- 3 Fintech Stocks With Good 2021 Prospects
- Oracle Announces Game-Changing News for the AI Industry
- What is the S&P/TSX Index?
- Netflix Adds 19 Million Subscribers, Growth Is Far From Over
- How Technical Indicators Can Help You Find Oversold Stocks
- Tempus AI: A Game-Changer in AI-Powered Healthcare
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
